PERIPHERAL NEUROPATHY

Your feet are reporting a fire that started in your bloodstream, not your shoes.

Burning, numbness, and unsteadiness on your feet usually trace back to small nerve fibers damaged by years of metabolic stress, most often diabetes but not only diabetes. The nerve is the messenger. The disease is upstream, and treating only the message leaves the disease running.

A clinician performing a monofilament sensation test on a patient's foot.

What it feels like, and where it starts

Peripheral neuropathy shows up first in the longest nerves in the body, which is why it starts in the feet and climbs — a stocking-glove pattern, burning or electric at rest, numb enough that patients step on things without noticing, and unsteady enough that falls become a real risk before pain ever does. Diabetic neuropathy is the most common cause we see, but prediabetes, alcohol, chemotherapy, autoimmune disease, and B12 deficiency all damage the same small fibers by different routes, which is why the workup does not stop at a glucose number.

The mechanism underneath the burning

Two biological drivers do most of the damage. The first is hyperinsulinemia and insulin resistance themselves — years of elevated insulin, not just elevated glucose, injure nerve fibers directly and predict neuropathy even in patients whose blood sugar looks acceptable on paper. The second is a combined microvascular and mitochondrial failure: the small vessels feeding the nerve narrow and stiffen, starving the fiber of oxygen, while the mitochondria inside the nerve cell lose their capacity to buffer the resulting oxidative stress. The nerve is, quite literally, running out of both fuel and the machinery to burn it cleanly. The third driver is economic and behavioral: the diet that reverses insulin resistance costs more and takes more time than the diet that caused it, and a patient working two jobs on a fixed income is not choosing neuropathy, they are choosing the food and the schedule available to them. We do not treat that as a footnote.

I spent the first twenty years of my career telling patients their A1C was “not too bad” because it sat just under the diabetes cutoff. I was wrong. The nerve damage in prediabetes starts well before that line, and by the time a chart says diabetic, the small fibers have often been losing ground for years. That changed how early we look now.

What we measure

Beyond the exam — monofilament testing for light touch, vibration sense, reflexes, and a look at gait and balance — bloodwork is part of the first visit, not an add-on: fasting insulin and HbA1c at minimum, because insulin resistance can precede an abnormal A1C by years. Where the pattern is atypical, asymmetric, or progressing unusually fast, we widen the workup rather than assume diabetes and move on.

Interventional and device-based options

AURICULAR NERVE STIMULATION

For diabetic peripheral neuropathy specifically, we offer a percutaneous nerve stimulator applied entirely at the ear — four small titanium electrode arrays placed in a roughly 30-minute in-office procedure under topical anesthesia, targeting the auricular branches so the device acts on the vagal pathway rather than on the painful nerve directly. There is no sedation, no activity restriction afterward, and nothing left permanently implanted; the electrodes come out at the end of a standardized 20-day course. A 2025 retrospective chart review of 83 patients with painful diabetic neuropathy reported substantial reductions in reported pain scores over 90 days alongside improvements in HbA1c and glucose — but the study was uncontrolled and non-randomized, and its own authors named placebo effect and regression to the mean as confounders they could not rule out. We offer this device as a real option with real early signal, not as a cure with proof behind it yet, and we say so plainly before you decide.

SPINAL CORD STIMULATION

For painful diabetic neuropathy that has not responded to medication and topical or lifestyle measures, spinal cord stimulation has meaningfully stronger evidence behind it. A 2026 meta-analysis of randomized trials found clinically significant improvements in both pain and quality of life for patients receiving SCS added to conventional management, without an increase in complication rates. It is a bigger step — a trial period followed by a permanent implant if the trial succeeds — and we reserve it for patients who have exhausted the smaller steps first.

The terrain program

Neither device reverses insulin resistance. Reducing the driver that is killing the nerve fiber in the first place is the terrain half of the plan — time-restricted eating, targeted movement that improves microvascular flow without traumatizing already-fragile feet, and the same in-house Acceptance and Commitment Therapy we build into every chronic pain protocol, because the frustration of a numb, unpredictable foot has a behavioral cost of its own. See metabolic health and pain for how that piece is structured.

Where surgery does not fit

Surgery does not treat diabetic peripheral neuropathy. There is no operation that repairs a small fiber damaged by years of hyperinsulinemia and microvascular starvation, and we will tell you that directly rather than let an implant conversation imply otherwise — the stimulator devices above are placed surgically, but they modulate the pain signal, they do not reverse the underlying nerve injury. Nerve decompression surgery has a role in a narrower, different diagnosis — a single nerve physically entrapped at a specific site — and that distinction is worth getting right before anyone operates.

Red flags that change the visit

  • A foot ulcer, wound, or area of skin breakdown — needs same-day wound care evaluation regardless of pain level, because numbness hides infection until it is advanced.
  • Rapid, asymmetric onset over days rather than months — points away from typical diabetic neuropathy and toward a cause that needs faster workup.
  • Weakness, not just numbness — a motor component changes the differential and the urgency.
  • New falls or a sudden change in balance — warrants evaluation before the next fall causes a fracture. See when it is an emergency.

Common questions

Is the ear device the same as an implant?

Nothing stays in permanently — the electrode arrays are removed at the end of the 20-day course. It is a device classification the FDA lists as a peripheral nerve stimulator for pain relief, placed and removed in-office. Peripheral nerve stimulation covers the broader category this device belongs to.

Will normalizing my blood sugar reverse the nerve damage?

It stops the damage from progressing more reliably than it reverses what is already lost, and how much recovers depends heavily on how long the nerve was starved before treatment started. This is the case for early evaluation rather than waiting for pain to become severe. See when injections stop working for how we reassess a plan that has plateaued.

Do I need to be diabetic for this to apply to me?

Prediabetes, alcohol use, certain chemotherapy drugs, and B12 deficiency all cause peripheral neuropathy through overlapping but distinct mechanisms, and the workup accounts for that from the first visit regardless of a diabetes diagnosis. What to expect covers how that first visit is structured.

Is this covered by insurance?

Coverage depends on your specific plan and documented medical necessity, and prior authorization is not itself a promise of payment — we walk through what your plan covers before any device or procedure, not after. Peripheral nerve stimulation for chronic intractable pain is a covered Medicare category nationally, which is a starting point, not a guarantee; spinal cord stimulation follows a similar coverage path.

Related reading

We will treat the nerve and the blood feeding it, not just the burning

A neuropathy plan built on devices alone leaves the disease driving underneath it. We will tell you what the bloodwork shows, what device or block fits your pattern, and what the terrain plan looks like — together, not as separate appointments.

4479 Woodson Rd, Suite 401
St. Louis, MO 63134
Next to St. Louis Lambert International Airport, off I-70 at Woodson Road.

Sources

  • Staats PS et al. Combined minimally invasive vagal cranial nerve and trigeminocervical complex peripheral nerve stimulation produces prolonged improvement of severe painful peripheral neuropathy and hyperglycemia in type 2 diabetes. Frontiers in Neuroscience, 2025. PubMed 40933195
  • Awad G et al. Spinal Cord Stimulation Improves Pain and Quality of Life in Painful Diabetic Neuropathy: A Meta-Analysis of Randomized Trials. Neuromodulation, 2026. PubMed 41984006
  • Callaghan B, Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Annals of Neurology, 2013. PubMed 23929529